Which companies are IVF HARTMANN's closest peers?

The cockpit's peer set: COLTENE (CLTN.SW), Star Sports Medicine (1609.HK), Chongqing Xishan Science and Technology (688576.SS), Mobia Medical (MOBI), Jiangsu Apon Medical Technology (300753.SZ), Shenzhen Bioeasy Biotechnology (300942.SZ), Embecta (EMBC), InBody (041830.KS).

How has IVF HARTMANN stock performed?

Over six months to 6 Nov 2026 the shares returned -5.3% against -11.2% for the median peer; over one year -9.8%.

← CockpitCompetitor Analysis › VBSN.SW IVF HARTMANN Holding AGOpen in the cockpit ↗

IVF HARTMANN Holding AGVBSN.SWCompetitor analysis, valuation and peers

Switzerland · CHF·Health Care›Medical Specialties

Momentum weak 32

Competitor Analysis ▸ Charts Open in the cockpit

Mkt cap

$364M

US dollars, full cap

Free float

23%

of shares outstanding

$/day

$56,270

20-day average traded

Fwd P/E

n/m

no positive forecast

ROIC−WACC

+31.4 pp

WACC 5.0%

Hurdle

-11 pp

Req g minus delivered

Close · CHFCHF 125.00

1D0.0%

1W0.0%

1M0.0%

3M0.0%

6M-5.3%

YTD-12.6%

1Y-9.8%

ATR %1.6%

52w lowhigh16.7% off high

What IVF HARTMANN does

Employees: 316

IVF HARTMANN at a glance

Size IVF HARTMANN (VBSN.SW) is a Switzerland Health Care company (Medical Specialties) with a market value of $364M, the 151st largest of 158 Switzerland companies the cockpit tracks. Shares closed at CHF 125.00 on 6 Nov 2026.

Performance Over six months the shares fell 5.3%, against -11.2% for the median peer and +11.6% for the Switzerland market (cap-weighted) — 9th highest of 20 in its peer set.

Growth Revenue grew 6.9% over the last twelve months (peer median +11.5%); the operating margin is 14.0% (peer median 2.6%).

Valuation It trades at 1.1× enterprise value to sales against a peer median of 5.0× (3rd cheapest of 20).

Price implies For today's price to make sense, revenue must grow about -13% a year for seven years (Req g). Recent delivered growth is -1%, so the hurdle is -11 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 31.4 points above its cost of capital (5.0% WACC).

Relative performance

Six months, rebased to 100: IVF HARTMANN against the median of its 20 peers (local-currency closes).

IVF HARTMANN financials

Reported figures in CHF; fiscal year ends 2025-12-31. TTM = trailing twelve months.
	TTM	FY2025	FY2024	FY2023	FY2022
Revenue	CHF 170M	CHF 162M	CHF 159M	CHF 148M	CHF 151M
Revenue growth	—	+2%	+7%	-2%	—
Gross profit	CHF 55.4M	CHF 52.9M	CHF 54.1M	CHF 45.0M	CHF 43.9M
EBITDA	CHF 28.6M	CHF 21.8M	CHF 24.7M	CHF 17.6M	CHF 16.1M
Net income	CHF 20.3M	CHF 18.3M	CHF 20.3M	CHF 15.1M	CHF 11.2M
Free cash flow	CHF 23.3M	CHF 17.7M	CHF 18.2M	CHF 31.8M	CHF 15.5M
Capital expenditure	CHF 3.36M	CHF 3.97M	CHF 2.58M	CHF 2.42M	CHF 2.71M
Total debt	n/a	CHF 1.39M	CHF 1.30M	CHF 1.34M	CHF 931,000

Quarterly statements and history in the cockpit →

IVF HARTMANN competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

Up and to the right = strong over both horizons. IVF HARTMANN is the large dot.

Fundamentals: revenue growth against valuation

Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. IVF HARTMANN is the large dot.

Capital: growth delivered against growth the price implies

Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. IVF HARTMANN is the large dot.

IVF HARTMANN competitors and peer comparison

How IVF HARTMANN compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

IVF HARTMANN against its 20 peers (data as of 6 Nov 2026)
Measure	VBSN.SW	Peer median	Rank in peer set
1-month return	0.0%	-7.4%	5th highest of 21
6-month return	-5.3%	-11.2%	9th highest of 20
Distance from 52-week high	-16.7%	-41.5%	4th highest of 21
Revenue growth (TTM)	+6.9%	+11.5%	10th lowest of 20
Operating margin	14.0%	2.6%	7th highest of 20
EV / Sales	1.1×	5.0×	3rd cheapest of 20
Growth the price implies (Req g, 7 yrs)	-12.7%	0.1%	5th least demanding of 12
Growth delivered (Del g)	-1.3%	-0.1%	5th lowest of 12
Hurdle (Req g minus delivered)	-11.4 pp	+8.7 pp	5th least demanding of 12
ROIC minus cost of capital	+31.4 pp	-5.2 pp	2nd highest of 17
EV / EBITDA	6.8×	9.1×	5th cheapest of 10
Net debt / EBITDA	-3.6×	-3.7×	5th most indebted of 10

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
Company	Market	Market cap	6M return	Revenue growth	Op. margin	EV / Sales	Req g	Delivered g
IVF HARTMANN VBSN.SW	Switzerland	$364M	-5%	+7%	14%	1.1×	-12.7%	-1.3%
COLTENE CLTN.SW	Switzerland	$361M	+3%	-2%	8%	1.4×	0.1%	-0.7%
Star Sports Medicine 1609.HK	Hong Kong	$367M	-76%	+23%	37%	3.7×	-13.2%	+36.8%
Chongqing Xishan Science and Technology 688576.SS	China	$356M	-26%	-23%	-29%	6.5×	n/a	n/a
Mobia Medical MOBI	United States	$373M	n/a	+105%	-145%	6.4×	n/a	n/a
Jiangsu Apon Medical Technology 300753.SZ	China	$376M	-27%	-15%	-10%	8.0×	22.4%	-5.1%
Shenzhen Bioeasy Biotechnology 300942.SZ	China	$352M	-27%	+12%	-2%	8.1×	n/a	n/a
Embecta EMBC	United States	$351M	+70%	-8%	26%	1.6×	-19.9%	-0.1%
InBody 041830.KS	South Korea	$378M	+43%	+21%	19%	1.4×	-7.6%	+16.9%
Yantai Zhenghai Bio-Tech 300653.SZ	China	$380M	-23%	-8%	17%	6.0×	20.0%	+4.4%
ACRO Biomedical 6748.TWO	Taiwan	$347M	+129%	+45%	-178%	200.7×	n/a	n/a
Nanjing Medlander Medical Technology 688273.SS	China	$385M	-44%	-12%	8%	5.0×	39.0%	+5.2%
BioNote 377740.KS	South Korea	$343M	-10%	+13%	16%	0.8×	-19.8%	-28.5%
Chemclin Diagnostics 688468.SS	China	$342M	-23%	-14%	6%	6.2×	31.9%	-4.5%
Clarity Pharmaceuticals CU6.AX	Australia	$386M	-48%	n/a	n/a	n/a	n/a	n/a
Orchestra BioMed OBIO	United States	$341M	+41%	+986%	-181%	9.8×	n/a	n/a
Stratec SBS.DE	Germany	$341M	+41%	-3%	3%	1.6×	n/a	n/a
OrbusNeich Medical 6929.HK	Hong Kong	$389M	-3%	+16%	23%	1.0×	-18.5%	+15.4%
Peijia Medical 9996.HK	Hong Kong	$340M	-34%	+21%	-13%	2.9×	n/a	n/a
CapsoVision CV	United States	$336M	-11%	+15%	-217%	23.6×	n/a	n/a
Jiangsu Nanfang Medical 603880.SS	China	$336M	+4%	-7%	-15%	4.7×	22.5%	-10.9%

Questions

Which companies are IVF HARTMANN's closest peers?: The cockpit's peer set: COLTENE (CLTN.SW), Star Sports Medicine (1609.HK), Chongqing Xishan Science and Technology (688576.SS), Mobia Medical (MOBI), Jiangsu Apon Medical Technology (300753.SZ), Shenzhen Bioeasy Biotechnology (300942.SZ), Embecta (EMBC), InBody (041830.KS).
Is IVF HARTMANN expensive compared with its peers?: On ev / sales it trades at 1.1× against a peer median of 5.0×, 3rd cheapest of 20 in its peer set. For today's price to make sense, revenue must grow about -13% a year for seven years (Req g). Recent delivered growth is -1%, so the hurdle is -11 pp: the price already allows for a slowdown.
How has IVF HARTMANN stock performed?: Over six months to 6 Nov 2026 the shares returned -5.3% against -11.2% for the median peer; over one year -9.8%.